Parent Project Muscular Dystrophy

Solid Biosciences Inc. has shared that the first participant has been dosed in IMPACT DUCHENNE, the company’s multi-country, placebo-controlled, randomized, double-blind, Phase 3 clinical trial inv...

Duchenne was added to the Recommended Uniform Screening Panel (RUSP) (RUSP) on December 16, 2025, and in the months since, that decision, coupled with our continued advocacy efforts, have driven meaningful a...

Entrada Therapeutics has announced positive topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of the Phase 1/2 ELEVATE-44-201 study evaluating EN...

This past weekend, PPMD kicked off our 2026 PPMD Together series in Philadelphia, Pennsylvania. Individuals with Duchenne and Becker, their families, clinicians, and industry partners gathered for a day and a half full of connection and community.

On April 24, 2026, PPMD, in collaboration with the Muscular Dystrophy Association (MDA) and the Little Hercules Foundation (LHF), convened a Duchenne Newborn Screening (NBS) Stakeholder Meeting in Philadelphia. The meeting’s main goal was to gather together industry partners in Duchenne to establish a foundation of understanding of the process of state implementation, and to ...